Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience

BACKGROUND: Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months. Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking. The study results of innovativ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Case Rep Oncol Med
Autores principales: Karivedu, Vidhya, Eldessouki, Ihab, Taftaf, Ahmad, Zhu, Zheng, Makramalla, Abouelmagd, Karim, Nagla Abdel
Formato: Artigo
Lenguaje:Inglês
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6501230/
https://ncbi.nlm.nih.gov/pubmed/31179139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3560640
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares